Novartis
NVS
1,080 hedge funds and large institutions have $18B invested in Novartis in 2021 Q3 according to their latest regulatory filings, with 57 funds opening new positions, 368 increasing their positions, 410 reducing their positions, and 79 closing their positions.
213% more call options, than puts
Call options by funds: $501M | Put options by funds: $160M
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
0.24% more ownership
Funds ownership: 8.79% → 9.03% (+0.24%)
3% less funds holding
Funds holding: 1,119 → 1,080 (-39)
9% less capital invested
Capital invested by funds: $19.8B → $18B (-$1.8B)
10% less repeat investments, than reductions
Existing positions increased: 368 | Existing positions reduced: 410
28% less first-time investments, than exits
New positions opened: 57 | Existing positions closed: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$433M |
| 2 |
Renaissance Technologies
New York
|
+$80.7M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$67M |
| 4 |
Natixis Advisors
Boston,
Massachusetts
|
+$66M |
| 5 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$63.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mawer Investment Management
Calgary,
Alberta, Canada
|
-$196M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$172M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$66.9M |
| 4 |
WG
Welch Group
Birmingham,
Alabama
|
-$31.9M |
| 5 |
Ameriprise
Minneapolis,
Minnesota
|
-$28.2M |
NVS Hedge Fund Activity: Q3 2021 in Review
1,080 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Novartis (NVS) for Q3 2021, worth a combined $18B — down 9.1% from $19.8B a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of NVS and 57 opened new positions — a net loss of 22 holders — while 410 trimmed existing stakes and 368 added.
The largest buyer was Dodge & Cox, adding an estimated $433M. The largest seller was Mawer Investment Management, cutting an estimated $196M.
- 1,080 institutional investors held Novartis (NVS) as of Q3 2021, down from 1,119 in Q2 2021.
- Funds reported $18B of Novartis stock for Q3 2021, down 9.1% quarter-over-quarter.
- 57 funds opened new Novartis positions in Q3 2021 and 79 closed out, a net change of -22 holders.
- The largest Novartis buyer in Q3 2021 was Dodge & Cox, an estimated $433M added.
- The largest Novartis seller in Q3 2021 was Mawer Investment Management, an estimated $196M sold.
Based on aggregated 13F filings for Q3 2021.